Immupharma Share News (IMM)
IMM Share
IMM Share
IMM Share
IMM Share
IMM
IMM Share
IMM Level 2
IMM Live
IMM Broker
IMM Directors
IMM Financial
IMM
IMM Short
IMM
Last checked at -
LONDON (Alliance News) - ImmuPharma PLC said it is in final preparations to open a managed access programme for its lupus drug Lupuzor to patients in Europe.Shares in the drug discovery and
Read more
(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Tuesday that on 25 February, the peer reviewed research journal Nature Communications published a fundamental scientific publication on the proprietary technology 'Urelix' from its subsidiary Ureka.
Read more(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on its clinical development collaboration agreement for its 'Nucant' cancer programme on Monday, with specialist oncology development partner Incanthera.
Read moreLONDON (Alliance News) - ImmuPharma PLC on Friday said it is currently in the process of making Lupuzor, its drug for the treatment of lupus, available to patients via its managed access drug said
Read more(Sharecast News) - Drug discovery and development outfit Immupharma has progressed its managed access programme on Lupzor as planned, with patient recruitment in France and the UK expected to follow the firm's analysis of regulatory processes across the EU.
Read more(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced its interim results for the six months ended 30 June on Wednesday - a period in which its revenue remained negligible at £0.07m, but its drug candidate 'Lupuzor' demonstrated a superior response rate over placebo in its primary analysis on the full set of 202 patients.
Read more(Sharecast News) - IAG: UBS downgrades to neutral with a target price of 705p.
Read moreLONDON (Alliance News) - ImmuPharma PLC said on Wednesday it continues to progress its lupus treatment Lupuzor, as it saw a widened loss for the first half of 2018 due to higher costs and lower a
Read more(Sharecast News) - For the 'Inside the City' column in the Sunday Times, Sabah Meddings wrote a "cautionary tale" about former biotech darling Immupharma, which last year saw its shares rise 227% over a year.
Read moreLONDON (Alliance News) - ImmuPharma PLC said Friday it signed a clinical development collaboration for the Nucant cancer programme with Incanthera Ltd, a specialist oncology development the terms
Read more(Sharecast News) - Pharmaceutical firm ImmuPharma on Friday signed an agreement for a managed access programme (MAP) for its "ground-breaking" new lupus treatment, Lupuzor.
Read moreLONDON (Alliance News) - ImmuPharma PLC said Thursday that its pre-clinical studies of the P140 peptide showed positive results in the treatment of chronic inflammatory demyelinating were trading
Read moreLONDON (Alliance News) - ImmuPharma PLC said Tuesday it continues to be "excited" by its future potential despite a widened loss for 2017.The drug development company reported a a
Read moreLONDON (Alliance News) - Drug development company ImmuPharma PLC said on Friday it has been informed by Simbec-Orion that the data-base lock for the Lupuzor pivotal phase III
Read more(ShareCast News) - Specialist drug discovery and development company ImmuPharma provided further details of patient participation on Wednesday, following confirmation in December that the company had successfully completed patient recruitment into its pivotal 52-week Phase III clinical trial of Lupu
Read more
Last checked at